ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
The decision is based on the phase 3 DESTINY-Breast11 trial
The decision is based on the phase 3 DESTINY-Breast11 trial
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The presentations underscore the company’s deep expertise in dermatology and immunology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Subscribe To Our Newsletter & Stay Updated